Biotech Late Stage Investors & VC Firms
360 firms in this list, with a median first check of $1M. 82 of them lead rounds. Generated from verified public data and updated continuously.
Cultivian Sandbox Ventures
ChicagoSeed–Late Stage$5M – $15M
8 people
New Rhein Healthcare Investors, LLC
PhiladelphiaSeries B–Late Stage
15 people
ISA Ventures
Cedar RapidsPre-Seed–Late Stage$25K – $1M
4 people
Fine Structures Ventures
CambridgePre-Seed–Late Stage
10 people
Redesign Health
New YorkSeed–Late Stage
13 people
Yuanta Investment
SeoulSeed–Late Stage$1M – $15M
20 people
Tin Alley Ventures
MelbourneSeed–Late Stage
13 people
Infinitas Capital
Pre-Seed–Late Stage
17 people
GEOC
ShanghaiSeed–Late Stage$3M – $10M
10 people
Maxpro Ventures
TaipeiSeed–Late Stage
7 people
Sycamore Ventures
PrincetonGrowth–Late Stage$5M – $20M
13 people
Ligand Pharmaceuticals
JupiterLate Stage
15 people
Prospect Venture Partners
Menlo ParkSeed–Late Stage$3M – $5M
3 people
TVM Capital
MunichSeed–Late Stage$1.1M – $16.2M
10 people
Texas Ventures
HoustonSeed–Late Stage
6 people
Corner Ventures
New YorkSeed–Late Stage
15 people
ALIVE Israel HealthTech Fund
SavyonSeed–Late Stage
10 people
Endeavour Vision
GenevaLate Stage
6 people
Shepherd Ventures
San DiegoSeries A–Late Stage$750K – $3M
6 people
Partners Investment Co. Ltd.
SeoulSeries A–Late Stage
11 people
Amgen Ventures
Thousand OaksSeed–Late Stage$1M – $3M
2 people
Fresenius Medical Care Ventures
Bad HomburgSeed–Late Stage
7 people
Soul Ventures
Series C–Late Stage
14 people
Recharge Thematic Ventures Management Llc
New YorkSeed–Late Stage
8 people
Related lists
Biotech Investors & VC Firms (2585)Biotech Seed Investors & VC Firms (2105)Late Stage Investors & VC Firms (1710)Biotech Series A Investors & VC Firms (1693)Biotech Investors & VC Firms in North America (1688)Biotech Investors & VC Firms in United States (1535)Biotech Investors & VC Firms in Europe (990)Biotech Pre-Seed Investors & VC Firms (987)Late Stage Investors & VC Firms in North America (915)Biotech Investors & VC Firms in Global (887)
Data sourced from public filings and firms' own websites — see our methodology.





















































































